Citius Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US17322U2078
USD
1.25
-0.01 (-0.79%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Citius Pharmaceuticals, Inc. stock-summary
stock-summary
Citius Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is focused on developing and commercializing care products with a focus on anti-infective products in adjunct cancer care and prescription products. It has three product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok product is designed to salvage the central venous catheters CVC, obviating the need to remove and replace the catheter. Mino-Wrap is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the steroid, halobetasol, with lidocaine.
Company Coordinates stock-summary
Company Details
11 Commerce Dr Fl 1 , CRANFORD NJ : 07016-3501
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 19 Schemes (8.14%)

Foreign Institutions

Held by 21 Foreign Institutions (0.91%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Leonard Mazur
Executive Chairman of the Board, Secretary
Mr. Myron Holubiak
President, Chief Executive Officer, Director
Mr. Suren Dutia
Independent Director
Dr. Eugene Holuka
Independent Director
Mr. William Kane
Independent Director
Mr. Howard Safir
Independent Director
Ms. Carol Webb
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-9 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 21 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.08

stock-summary
Return on Equity

-64.67%

stock-summary
Price to Book

0.32